Thursday, Nymox Pharmaceutical Corp. (NYMX) secured commitment for $15 million in equity financing from institutional investors. The new funding will be used for general corporate purposes. The financing gives the company the right to place common stock to the investors at a 3% discount to the market price of the company's stock. There are no warrants, price resets, and no restrictions on other corporate financing. The timing and amount of each placement is in the sole discretion of the company.
Nymox Pharmaceutical Corp., a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices. Its products include NicAlert and TobacAlert tests that use urine or saliva to detect use of and exposure to tobacco products; and AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer's disease.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.